$Novo-Nordisk A/S(NVO)$ The two drastic guidance cuts are a sign of poor control over the business and undermine the credibility of future outlooks.As of today, the company can focus on sales and the launch of new products in the pipeline (CagriSema in particular), but it's hard to completely turn around a business quickly in the pharma sector.That said, the numbers remain solid, especially margins, and the dividend appears more than sustainable. My concern, however, is that growth could remain in the single-digit territory over the coming years.So, looking at the next 5 to 10 years, much depends on how you assess the company’s current pipeline. Over an even longer horizon, there's still time to turn things around and Novo has an incredibly good tr
The U.S. pharmaceutical sector fell, Novo Nordisk (NVO.US) fell more than 3%
The U.S. pharmaceutical sector fell on Friday, failing to extend this week's gains. Novo Nordisk (NVO.US) fell more than 3%, Moderna (MRNA.US) fell more than 2.4%, Eli Lilly (LLY.US) fell more than 1%, and Pfizer (PFE.US) fell nearly 1%. On the news side, it is reported that the FDA may speed up drug review to reduce drug prices in the United States.